Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 endoscopic photodynamic therapy with ME2906 and ultrathin PDT probe in unresectable bile duct cancer
jRCT2041220118Phase 2Completed
- Sponsor
- Not applicable
- Start
- Feb 2023
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of talaporfin sodium in cholangiocarcinoma (CCA) and malignant biliary obstruction (MBO) (3 arms), sponsored by Not applicable. Primary endpoints: Phase Ia and Ib: Incidence of IEDLT and Phase II: 6-month non-recurrent biliary obstruction (Non-RBO) survival rate. Started Feb 2023; status: completed.
02
Drugs
talaporfin sodium
03
Conditions
cholangiocarcinoma (CCA)malignant biliary obstruction (MBO)
Beyond the preview
Go deeper on jRCT2041220118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041220118.